Proteintech, 67166-1-Ig-150ul, ACLY Monoclonal antibody

67166-1-Ig targets ACLY in WB, IHC, IF/ICC, IP, ELISA applications and shows reactivity with human, mouse, rat samples.
Tested Applications
Positive WB detected in: Jurkat cells, MCF-7 cells, HSC-T6 cells
Positive IHC detected in: human prostate cancer tissueNote: suggested antigen retrieval withTE buffer pH 9.0;(*) Alternatively, antigen retrieval may be performed withcitrate buffer pH 6.0
Positive IF/ICC detected in: A549 cells
Recommended dilution
Western Blot (WB): WB : 1:1000-1:10000
Immunohistochemistry (IHC): IHC : 1:1000-1:4000
Immunofluorescence (IF)/ICC: IF/ICC : 1:400-1:1600
Background Information
ACLY(ATP-citrate synthase) is also named as ACL. It is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA. ACLY serves as not only a target in oxygenated cells for suppression of lipid synthesis and histone acetylation, but also as a susceptible target in hypoxic cells to restore inhibition of glycolysis. In nonsmall cell lung carcinoma and hepatocellular carcinoma, ACLY is overexpressed compared with normal parenchyma suggesting that ACLY may represent a common target among highly malignant tumors(PMID:19795461). This protein has 2 isoforms produced by alternative splicing.